Manoj Kumbhare, Nishant Dattatray Pagere*, Bhagwan Ide ,Harshali Gode, Arshad Shaikh

Department of Pharmaceutical Chemistry, SMBT College of Pharmacy, Dhamangaon, Nashik – 422403, India

* Address    for  Correspondence:

Nishant Dattatray Pagere

Department of Pharmaceutical Chemistry, S. M. B. T. College of Pharmacy, Dhamangaon, Nashik, M.S. India-422 403. Affiliated to Savitribai Phule Pune University

Email: nishantpagere789@gmail.com

Contact no: 8010854337

Abstract

This review looks at the pharmacokinetics, safety, and effectiveness of taletrectinib, a novel inhibitor that targets both ROS1 and NTRK, in patients with solid tumors and ROS1-positive non-small cell lung cancer (NSCLC).  Objective response rates (ORR), progression-free survival (PFS), intracranial efficacy, and safety profiles are evaluated in the Review using phase I and phase II clinical trials, including both domestic and foreign research projects.  Findings show that taletrectinib has a promising anticancer impact, good CNS penetration, and a solid safety record, especially in patients with brain metastases.  These results imply that ROS1-positive cancers may benefit from taletrectinib as a treatment.

Keywords  Clinical studies, Non-small cell lung cancer, ROS1, Taletrectinib, Tyrosine kinase inhibitor

PDF  Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib.pdf